



Toxicological Profile for Acrolein

April 2025



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute-, intermediate-, and chronic-duration exposures;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health due to acute-, intermediate-, and chronic-duration exposures; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Christopher M. Reh, Ph.D.

Associate Director

Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

VERSION HISTORY

Date	Description
April 2025	Final toxicological profile released
May 2024	Draft for public comment toxicological profile released
August 2007	Final toxicological profile released
December 1990	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Sam Keith, M.S., C.H.P. (Lead)
Brittany Szafran, D.V.M., Ph.D., D.A.B.T.
Mohammad Shoeb, Ph.D.
Carolyn Harper, Ph.D.

Julie Melia, Ph.D., D.A.B.T.
Zach Guerrette, Ph.D., D.A.B.T.
Kim Zaccaria, Ph.D., D.A.B.T.
Heather Carlson-Lynch, M.S., D.A.B.T.
Claire Heit, Ph.D.
Deborah M. Herber, Ph.D.
Jenny S. Crisman, B.S.
Ramsey Hanna, Ph.D.

ATSDR, Office of Innovation and Analytics,
Toxicology Section, Atlanta, GA

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Office of Community Health Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Sciences; NCEH, Division of Environmental Health Science and Practice; EPA, Office of Research and Development; EPA, Office of Water.

PEER REVIEWERS

1. David Williams, Ph.D.; University Distinguished Professor; Department of Environmental and Molecular Toxicology; Oregon State University; Corvallis, Oregon
2. Robert Herrick, Sc.D.; Harvard School of Public Health; Department of Environmental Health; Boston, Massachusetts
3. Edward Levin, Ph.D.; Professor; Duke University; Durham, North Carolina

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER	ii
FOREWORD	iii
VERSION HISTORY	iv
CONTRIBUTORS & REVIEWERS	v
CONTENTS	vi
LIST OF FIGURES	viii
LIST OF TABLES	ix
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1 OVERVIEW AND U.S. EXPOSURES	1
1.2 SUMMARY OF HEALTH EFFECTS	2
1.3 MINIMAL RISK LEVELS (MRLs)	7
CHAPTER 2. HEALTH EFFECTS	11
2.1 INTRODUCTION	11
2.2 DEATH	67
2.3 BODY WEIGHT	68
2.4 RESPIRATORY	70
2.5 CARDIOVASCULAR	84
2.6 GASTROINTESTINAL	90
2.7 HEMATOLOGICAL	91
2.8 MUSCULOSKELETAL	92
2.9 HEPATIC	92
2.10 RENAL	95
2.11 DERMAL	95
2.12 OCULAR	96
2.13 ENDOCRINE	97
2.14 IMMUNOLOGICAL	98
2.15 NEUROLOGICAL	100
2.16 REPRODUCTIVE	102
2.17 DEVELOPMENTAL	103
2.18 OTHER NONCANCER	103
2.19 CANCER	104
2.20 GENOTOXICITY	106
2.21 MECHANISMS OF TOXICITY	111
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS	115
3.1 TOXICOKINETICS	115
3.1.1 Absorption	116
3.1.2 Distribution	117
3.1.3 Metabolism	118
3.1.4 Excretion	121
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	122
3.1.6 Animal-to-Human Extrapolations	128
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	128

3.3	BIOMARKERS OF EXPOSURE AND EFFECT	130
3.3.1	Biomarkers of Exposure.....	131
3.3.2	Biomarkers of Effect.....	132
3.4	INTERACTIONS WITH OTHER CHEMICALS	133
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION		135
4.1	CHEMICAL IDENTITY	135
4.2	PHYSICAL AND CHEMICAL PROPERTIES	135
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE		137
5.1	OVERVIEW	137
5.2	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	140
5.2.1	Production	140
5.2.2	Import/Export.....	142
5.2.3	Use	142
5.2.4	Disposal.....	143
5.3	RELEASES TO THE ENVIRONMENT	143
5.3.1	Air	144
5.3.2	Water.....	152
5.3.3	Soil	153
5.4	ENVIRONMENTAL FATE	153
5.4.1	Transport and Partitioning.....	153
5.4.2	Transformation and Degradation	154
5.5	LEVELS IN THE ENVIRONMENT.....	157
5.5.1	Air	158
5.5.2	Water.....	163
5.5.3	Sediment and Soil	164
5.5.4	Other Media	164
5.6	GENERAL POPULATION EXPOSURE.....	166
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	170
CHAPTER 6. ADEQUACY OF THE DATABASE.....		172
6.1	INFORMATION ON HEALTH EFFECTS.....	172
6.2	IDENTIFICATION OF DATA NEEDS	172
6.3	ONGOING STUDIES.....	180
CHAPTER 7. REGULATIONS AND GUIDELINES		182
CHAPTER 8. REFERENCES		184
APPENDICES		
APPENDIX A.	ATSDR MINIMAL RISK LEVEL WORKSHEETS	A-1
APPENDIX B.	LITERATURE SEARCH FRAMEWORK FOR ACROLEIN	B-1
APPENDIX C.	FRAMEWORK FOR ATSDR'S SYSTEMATIC REVIEW OF HEALTH EFFECTS DATA FOR ACROLEIN	C-1
APPENDIX D.	USER'S GUIDE	D-1
APPENDIX E.	QUICK REFERENCE FOR HEALTH CARE PROVIDERS	E-1
APPENDIX F.	GLOSSARY	F-1
APPENDIX G.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....	G-1

LIST OF FIGURES

1-1. Health Effects Found in Humans and Animals Following Inhalation Exposure to Acrolein.....	3
1-2. Health Effects Found in Animals Following Oral Exposure to Acrolein.....	4
1-3. Summary of Sensitive Targets of Acrolein – Inhalation	8
1-4. Summary of Sensitive Targets of Acrolein – Oral	9
2-1. Overview of the Number of Studies Examining Acrolein Health Effects.....	14
2-2. Levels of Significant Exposure to Acrolein – Inhalation	35
2-3. Levels of Significant Exposure to Acrolein – Oral.....	55
3-1. Metabolism of Acrolein.....	120
5-1. Number of NPL Sites with Acrolein Contamination.....	137
6-1. Summary of Existing Health Effects Studies on Acrolein by Route and Endpoint.....	173

LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for Acrolein	10
2-1. Levels of Significant Exposure to Acrolein – Inhalation	15
2-2. Levels of Significant Exposure to Acrolein – Oral.....	48
2-3. Levels of Significant Exposure to Acrolein – Dermal.....	64
2-4. Results of Epidemiological Studies Evaluating Exposure to Acrolein and Respiratory Effects.....	71
2-5. Respiratory Lesions in Animals Following Inhalation Exposure to Acrolein.....	75
2-6. Respiratory Function in Animals Following Inhalation Exposure to Acrolein	79
2-7. Lung Weight in Animals Following Inhalation Exposure to Acrolein.....	80
2-8. RD ₅₀ Values in Animals Following Inhalation Exposure to Acrolein.....	81
2-9. Results of Meta-analysis by Liu et al. 2023a.....	82
2-10. Results of Epidemiological Studies Evaluating Exposure to Acrolein and Cardiovascular Effects.....	85
2-11. Genotoxicity of Acrolein <i>In Vitro</i>	106
2-12. Genotoxicity of Acrolein <i>In Vivo</i>	109
3-1. Metabolite Levels (Percent Sample Radioactivity) in Urine of Rats after Intravenous or Oral Dosing with 2.5 mg/kg Acrolein	121
4-1. Chemical Identity of Acrolein	135
4-2. Physical and Chemical Properties of Acrolein	136
5-1. Facilities that Produce, Process, or Use Acrolein.....	141
5-2. Releases to the Environment from Facilities that Produce, Process, or Use Acrolein	144
5-3. Acrolein in Emissions from Combustion	146
5-4. Acrolein Emissions to the Air Based on 2017 National Emissions Inventory (NEI) by Emission Sector	147
5-5. Acrolein Emissions to the Air Based on 2020 National Emissions Inventory (NEI) by Facility Type.....	149
5-6. Acrolein Emissions from Building Material.....	151
5-7. Lowest Limit of Detection Based on Standards	157
5-8. Summary of Environmental Levels of Acrolein.....	158

5-9. Acrolein Levels in Water, Soil, and Air of National Priorities List (NPL) Sites.....	158
5-10. Summary of Annual Concentration of Acrolein (ppbv) Measured in Ambient Air at Locations Across the United States.....	159
5-11. Acrolein Concentrations (ppm) at Ground Level During Industrial Fires.....	161
5-12. Concentration of Acrolein ($\mu\text{g}/\text{m}^3$) Measured in Fresh and Aged Western U.S. Wildfire Smoke.....	161
5-13. Acrolein Concentrations in Indoor Air.....	162
5-14. Acrolein Content in Foods and Beverages	165
5-15. Reasonable Maximum Exposure of Acrolein for Daily Inhalation Dose and Administered Dermal Dose in $\mu\text{g}/\text{kg}/\text{day}$ for the Target Person.....	167
5-16. 3-HPMA Concentration ($\mu\text{g}/\text{g}$ creatinine) in Urine of Firefighters Pre- and Post-Fire Response.....	171
6-1. Ongoing Studies on Acrolein.....	180
7-1. Regulations and Guidelines Applicable to Acrolein.....	182